Vertex Announces Program Updates For Type 1 Diabetes Portfolio; VX-264 Phase 1/2 Enrollment And Dosing Complete In Parts A And B: VX-264 Was Generally Safe And Well Tolerated; Efficacy Data Are Not Supportive Of Further Clinical Advancement

-0.01%

Vertex Pharmaceuticals Incorporated

VRTX

0.00

- VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement -

- Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 -

- Continue to progress multiple novel, research-stage immunoprotective approaches -

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced several updates on the Company's type 1 diabetes (T1D) portfolio.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.